Sugi Predict

Sugi Predict / Compounds / SCHEMBL646750

SCHEMBL646750

SCHEMBL646750

CC(C)(C)OC(=O)N[C@@H](CN)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 7/20 0.50
▸ CTSS P25774 6/20 0.50
▸ PPARA Q07869 7/20 0.48
▸ PPARG P37231 6/20 0.48
▸ CTSL P07711 1/20 0.48
▸ CTSB P07858 1/20 0.48
▸ ACE P12821 1/20 0.47
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ PPARD Q03181 2/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ IDO1 P14902 1/20 0.44
▸ ITGB3 P05106 1/20 0.44
▸ ITGA2B P08514 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206031 1.00 CTSK (0.50) CTSKCTSSPPARAPPARGCTSL
SCHEMBL1742210 1.00 CTSK (0.50) CTSKCTSSPPARAPPARGCTSL
Hydrochloric Acid SCHEMBL16235893 0.98 CTSK (0.49) CTSKCTSSPPARAPPARGCTSL
Hydrochloric Acid SCHEMBL14471562 0.98 CTSK (0.49) CTSKCTSSPPARAPPARGCTSL
SCHEMBL303955 0.86 CTSK (0.49) CTSKCTSSPPARAPPARGCTSL
SCHEMBL303956 0.86 CTSK (0.49) CTSKCTSSPPARAPPARGCTSL
SCHEMBL2612149 0.86 CTSK (0.49) CTSKCTSSPPARAPPARGCTSL
SCHEMBL25256775 0.85 CYP1A2 (0.47) CTSKCTSSCTSLCTSBCA1
SCHEMBL20783244 0.85 CYP1A2 (0.47) CTSKCTSSCTSLCTSBCA1
SCHEMBL2393366 0.85 CYP1A2 (0.47) CTSKCTSSCTSLCTSBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117903034-B DuO-5 important constituent segment Boc-Dap-Tra monocrystal and preparation method and application thereof 南京联宁生物制药有限公司 2024-11-05 — — CN claimed
CN-118724780-A Purification method of cytotoxin intermediate 南京联宁生物制药有限公司 2024-10-01 — — CN claimed
CN-117903034-A DuO-5 important constituent segment Boc-Dap-Tra monocrystal and preparation method and application thereof 南京联宁生物制药有限公司 2024-04-19 — — CN claimed
CN-106146612-B A kind of glyoxalase I irreversible inhibitor and its preparation method and application 成都大学 2019-09-27 — — CN claimed
CN-106146612-A One class GLO-I irreversible inhibitor and its production and use 成都大学 2016-11-23 — — CN claimed
CN-122070148-A Inhibitors of targeted fibroblast activation proteins 苏州博锐创合医药有限公司 2026-05-19 — — CN disclosed
US-12612429-B2 Derivatives of dolaproine-dolaisoleuine peptides AGENSYS, INC. (US) 2026-04-28 — — US disclosed
EP-4719381-A1 LIGAND-POLAR DRUG CONJUGATES Tripartite Therapeutics Inc. (TW) 2026-04-08 — — EP disclosed
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2026-03-12 — — US disclosed
US-12540141-B2 Spiropyrrolidine derived antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2026-02-03 — — US disclosed
US-20260022193-A1 METHODS OF TREATMENT USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 ZYMEWORKS BC INC (CA) 2026-01-22 — — US disclosed
EP-4651905-A1 NOVEL LINKERS FOR SUSTAINED DELIVERY OF THERAPEUTICS Eli Lilly and Company (US) 2025-11-26 — — EP disclosed
US-6423840-B1 FORMING N-ACYLAMINO COMPOUND VERTEX PHARMACEUTICALS INCORPORATED 2002-07-23 — — US disclosed
US-6258948-B1 AN N-ACYLAMINO COMPOUND; ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES VERTEX PHARMACEUTICALS, INCORPORATED 2001-07-10 — — US disclosed
US-6204261-B1 Inhibitors of interleukin-1β Converting enzyme inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2001-03-20 — — US disclosed
US-6008217-A AN ENZYME INHIBITOR AGAINST INTERLEUKIN-1B, FOR TREATING APOPTOSIS-MEDIATED DISEASES, INCLUDING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, PROLIFERATIVE DISORDERS, INFECTIOUS DISEASES, AND DEGENERATIVE DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-12-28 — — US disclosed
US-5874424-A Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-02-23 — — US disclosed
EP-0869967-A2 INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME Vertex Pharmaceuticals Incorporated (US) 1998-10-14 — — EP disclosed
US-5656600-A MODIFIED POLYPEPTIDES CORVAS INTERNATIONAL, INC. (US) 1997-08-12 — — US disclosed
WO-1997022619-A2 INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 CTSK 4007/4885CTSS 3820/4885PPARA 514/4885
US-20260022193-A1 METHODS OF TREATMENT USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 IGSF11, ERBB2, PDCD1LG2 CTSK 2820/4885CTSS 2263/4885PPARA 2892/4885
US-12612429-B2 Derivatives of dolaproine-dolaisoleuine peptides DDOST, NGLY1, GRPR CTSK 2772/4885CTSS 2592/4885PPARA 4569/4885
US-12540141-B2 Spiropyrrolidine derived antiviral agents ACE2, NR3C2, ACE CTSK 1969/4885CTSS 1343/4885PPARA 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.